A Phase 1 interventional study of Cabotegravir tablet 30 mg once daily for 28 days. and Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1. in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-22.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 30th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 9th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 183rd largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2017, is one of 83 in phase 1, and was the 166th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
Cabotegravir (CAB) long-acting (LA) is a promising candidate for human immunodeficiency virus (HIV) pre exposure prophylaxis (PrEP) due to its potent antiretroviral activity and infrequent dosing requirements. Currently, the CAB concentrations achieved in the anatomical sites associated with sexual HIV transmission following the proposed 600 milligram (mg) intramuscular (IM) PrEP dose are unknown. These data will enhance our understanding of CAB distribution to the anatomical mucosal tissue believed to be relevant to sexual HIV-1 transmission and supplement the data to support future PrEP clinical trial development. The primary objective is to determine the PK concentrations of CAB following LA administration in plasma and in vaginal tissue (VT), cervical tissue (CT), and cervicovaginal fluid (CVF) in healthy women and in rectal tissue (RT) and rectal fluid (RF) in healthy men and women following a single 600 mg IM dose. This will be a Phase 1, open label study in healthy subjects to assess the pharmacokinetics of CAB LA in the plasma and mucosal locations associated with sexual HIV-1 transmission: VT, CT, CVF, RT and RF. The study will consist of a screening period, a 28-day oral lead-in phase at a dose of 30 mg per day followed by a 14-42 day washout period, and a single dose of CAB LA 600 mg as an IM (intragluteal) injection with compartmental pharmacokinetic (PK) sampling for up to 12 weeks. Subjects will return for safety assessments and plasma PK sampling at Week 24 and Week 36 post-injection and undergo a follow-up/withdrawal visit at Week 52 post-injection.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
This study's enrollment of 19 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTES: The QTc is the QT interval corrected for heart rate according to Bazette's formula (QTcB), machine-read or manually over-read. QTcB will be used to determine eligibility for an individual subject. Exclusion criteria for screening (ECG) (a single repeat is allowed for eligibility determination): Heart rate (\<45 and >100 beats per minute (bpm) for males and \<50 and >100 bpm for females; QRS duration: >120 msec; QTc interval: >450 msec for males and females
Evidence of previous myocardial infarction (pathologic Q waves, S-T segment changes (except early repolarization); History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA) or any clinically significant cardiac disease; Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block (2nd degree [type II] or higher), Wolf Parkinson White [WPW] syndrome); Sinus pauses > 3 seconds.
Additional Criteria for Female Subjects Only:
Additional Criteria for Male Subjects and Female Subjects who consent to rectal PK sampling:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
Drug: Cabotegravir tablet 30 mg once daily for 28 days. · Drug: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
Drug page: Cabotegravir
Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase
Cabotegravir Concentration in Blood Plasma Following IM Administration
Blood samples were collected to measure cabotegravir concentration in blood plasma following a single 600 mg IM dose at indicated time-points. Evaluable Pharmacokinetic (PK) Plasma Parameter Summary Population comprised of all participants who underwent plasma PK sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and had evaluable PK parameters estimated and no major protocol deviation.
Time frame: Day 1: Pre-dose and 4 hours; one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36 and 52 post-dose
Cabotegravir Concentration in Vaginal Tissue Following IM Administration (Female Participants)
Vaginal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points. Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM) comprised of all participants who underwent sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and have both evaluable PK and evaluable tissues-fluid parameters estimated in vaginal tissue/cervical tissue/cervicovaginal fluid/rectal tissue/rectal fluid.
Time frame: One sample on Day 3 and Week 8 post-dose
Cabotegravir Concentration in Cervical Tissue Following IM Administration (Female Participants)
Cervical tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Cabotegravir Concentration in Rectal Tissue Following IM Administration
Rectal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Cabotegravir Concentration in Rectal Fluid Following IM Administration
Rectal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
Vaginal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in blood plasma is presented.
Time frame: One sample on Day 3 and Week 8 post-dose
Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
Cervical tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in blood plasma is presented.
Time frame: One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of Cabotegravir Concentration in Cervicovaginal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration (Female Participants)
Cervicovaginal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervicovaginal fluid to cabotegravir concentration in blood plasma is presented.
Time frame: One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of Cabotegravir Concentration in Cervical Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervical tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in cervicovaginal fluid is presented.
Time frame: One sample on Day 3, 8, Weeks 4, 8 and 12
Ratio of Cabotegravir Concentration in Vaginal Tissue to Cabotegravir Concentration in Cervicovaginal Fluid Following IM Administration (Female Participants)
Vaginal tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in cervicovaginal fluid is presented.
Time frame: One sample on Day 3 and Week 8 post-dose
Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Blood Plasma Following IM Administration
Rectal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in blood plasma is presented.
Time frame: One sample on Day 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of Cabotegravir Concentration in Rectal Fluid to Cabotegravir Concentration in Blood Plasma Following IM Administration
Rectal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal fluid to cabotegravir concentration in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of Cabotegravir Concentration in Rectal Tissue to Cabotegravir Concentration in Rectal Fluid Following IM Administration
Rectal tissue and rectal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in rectal fluid is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Maximum Observed Concentration (Cmax) of Cabotegravir in Blood Plasma Following IM Administration
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose
Cmax of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Cervical tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Cmax of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Cmax of Cabotegravir in Rectal Tissue Following IM Administration
Rectal tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Cmax of Cabotegravir in Rectal Fluid Following IM Administration
Rectal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC[0-last]) for Cabotegravir in Blood Plasma Following IM Administration
Blood samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Day 1: Pre-dose, 4 hours, One sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose
AUC(0-last) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Cervical tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-last) of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-last) for Cabotegravir in Rectal Tissue Following IM Administration
Rectal tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-last) for Cabotegravir in Rectal Fluid Following IM Administration
Rectal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Area Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-inf]) for Cabotegravir in Blood Plasma Following IM Administration
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose
AUC(0-inf) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Cervical tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-inf) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-inf) for Cabotegravir in Rectal Tissue Following IM Administration
Rectal tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-inf) for Cabotegravir in Rectal Fluid Following IM Administration
Rectal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Area Under the Concentration Time Curve From Time Zero to Week (WK) 4 (AUC[0-WK4]) for Cabotegravir in Blood Plasma Following IM Administration
Blood samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8 and Week 4 post-dose
AUC(0-WK4) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Cervical tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8 and Week 4 post-dose
AUC(0-WK4) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8 and Week 4 post-dose
AUC(0-WK4) for Cabotegravir in Rectal Tissue Following IM Administration
Rectal tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8 and Week 4 post-dose
AUC(0-WK4) for Cabotegravir in Rectal Fluid Following IM Administration
Rectal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8 and Week 4 post-dose
Area Under the Concentration Time Curve From Time Zero to Week 8 (AUC[0-WK8]) for Cabotegravir in Blood Plasma Following IM Administration
Blood samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4 and 8 post-dose
AUC(0-WK8) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Cervical tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose
AUC(0-WK8) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose
AUC(0-WK8) for Cabotegravir in Rectal Tissue Following IM Administration
Rectal tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose
AUC(0-WK8) for Cabotegravir in Rectal Fluid Following IM Administration
Rectal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose
Area Under the Concentration Time Curve From Time Zero to Week 12 (AUC[0-WK12]) for Cabotegravir in Blood Plasma Following IM Administration
Blood samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8 and 12 post-dose
AUC(0-WK12) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Cervical tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-WK12) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-WK12) for Cabotegravir in Rectal Tissue Following IM Administration
Rectal tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
AUC(0-WK12) for Cabotegravir in Rectal Fluid Following IM Administration
Rectal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Apparent Terminal Phase Half-life (t1/2) of Cabotegravir in Blood Plasma Following IM Administration
Blood samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Day 1: Pre-dose, 4 hours, one sample on Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52 post-dose
t1/2 of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants)
Cervical tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
t1/2 of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
t1/2 of Cabotegravir in Rectal Tissue Following IM Administration
Rectal tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
t1/2 of Cabotegravir in Rectal Fluid Following IM Administration
Rectal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-last) in Cervical Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervical tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervical tissue to AUC(0-last) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-last) in Rectal Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration
Rectal tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal tissue to AUC(0-last) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-inf) in Cervical Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervical tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervical tissue to AUC(0-inf) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-inf) in Rectal Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration
Rectal tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal tissue to AUC(0-inf) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-Wk4) in Cervical Tissue to AUC(0-Wk4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervical tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervical tissue to AUC(0-WK4) in blood plasma is presented.
Time frame: One sample on Days 3, 8 and Week 4 post-dose
Ratio of AUC(0-Wk 4) in Rectal Tissue to AUC(0-Wk 4) in Blood Plasma for Cabotegravir Following IM Administration
Rectal tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal tissue to AUC(0-WK4) in blood plasma is presented.
Time frame: One sample on Days 3, 8 and Week 4 post-dose
Ratio of AUC(0-WK8) in Cervical Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervical tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervical tissue to AUC(0-WK8) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose
Ratio of AUC(0-WK8) in Rectal Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration
Rectal tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal tissue to AUC(0-WK8) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose
Ratio of AUC(0-WK12) in Cervical Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervical tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervical tissue to AUC(0-WK12) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-WK12) in Rectal Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration
Rectal tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal tissue to AUC(0-WK12) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-last) in Cervicovaginal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration-female Participants
Cervicovaginal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervicovaginal fluid to AUC(0-last) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-last) in Rectal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration
Rectal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal fluid to AUC(0-last) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-inf) in Cervicovaginal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervicovaginal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervicovaginal fluid to AUC(0-inf) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-inf) in Rectal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration
Rectal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal fluid to AUC(0-inf) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-WK4) in Cervicovaginal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervicovaginal fluid to AUC(0-WK4) in blood plasma is presented.
Time frame: One sample on Days 3, 8 and Week 4 post-dose
Ratio of AUC(0-WK4) in Rectal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration
Rectal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal fluid to AUC(0-WK4) in blood plasma is presented.
Time frame: One sample on Days 3, 8 and Week 4 post-dose
Ratio of AUC(0-WK8) in Cervicovaginal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervicovaginal fluid to AUC(0-WK8) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose
Ratio of AUC(0-WK8) in Rectal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration
Rectal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal fluid to AUC(0-WK8) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4 and 8 post-dose
Ratio of AUC(0-WK12) in Cervicovaginal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants)
Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervicovaginal fluid to AUC(0-WK12) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Ratio of AUC(0-WK12) in Rectal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration
Rectal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal fluid to AUC(0-WK12) in blood plasma is presented.
Time frame: One sample on Days 3, 8, Weeks 4, 8 and 12 post-dose
Cabotegravir Concentration in Vaginal Tissue Following Oral Administration (Female Participants)
Vaginal tissue samples were collected to measure cabotegravir concentration in vaginal tissue following oral 30 mg dose at indicated time-points.
Time frame: 24 hours post-dose on Day 28
Cabotegravir Concentration in Cervical Tissue Following Oral Administration (Female Participants)
Cervical tissue samples were collected to measure cabotegravir concentration in cervical tissue following oral 30 mg dose at indicated time-points.
Time frame: 24 hours post-dose on Day 28
Cabotegravir Concentration in Cervicovaginal Fluid Following Oral Administration (Female Participants)
Cervicovaginal fluid samples were collected to measure cabotegravir concentration in cervicovaginal fluid following oral 30 mg dose at indicated time-points.
Time frame: 24 hours post-dose on Day 28
Cabotegravir Concentration in Rectal Tissue Following Oral Administration
Rectal tissue samples were collected to measure cabotegravir concentration in rectal tissue following oral 30 mg dose at indicated time-points.
Time frame: 24 hours post-dose on Day 28
Cabotegravir Concentration in Rectal Fluid Following Oral Administration
Rectal fluid samples were collected to measure cabotegravir concentration in rectal fluid following oral 30 mg dose at indicated time-points.
Time frame: 24 hours post-dose on Day 28
Cabotegravir Concentration in Blood Plasma Following Oral Administration
Blood samples were collected to measure cabotegravir concentration in blood plasma following oral 30 mg dose at indicated time-points.
Time frame: 24 hours post-dose on Day 28
Number of Participants With Any Non-serious Adverse Event (Non-SAE) and Serious Adverse Events (SAE) Following Oral Administration of Cabotegravir
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.
Time frame: Up to Day 29
Number of Participants With Any Non-SAE and SAE Following IM Administration of Cabotegravir
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.
Time frame: Up to Week 52
Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Amino Transferase (AST) at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in ALT, ALP and AST at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Creatine Kinase at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in Creatine Kinase at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 8 and 12
Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Albumin and Total Protein at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in Albumin and Total Protein at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Calcium, Glucose, Potassium, Sodium and Urea Enzymatic Colorimetry at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and urea enzymatic colorimetry (UEC) following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in Calcium, Glucose, Potassium, Sodium and UEC at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and UEC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in Basophil Count, Eosinophil Count, Lymphocyte Count and Monocyte Count at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4 and 8
Change From Baseline in Total Neutrophil Count at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of hematology parameter; total neutrophils count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in Total Neutrophil Count at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of hematology parameters; total neutrophil count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Change From Baseline in Platelet Count and WBC Count at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Change From Baseline in Hemoglobin and MCHC at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Change From Baseline in MCH at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Mean Corpuscle Volume (MCV) at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Change From Baseline in MCV at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Hematocrit at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Change From Baseline in Hematocrit at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Red Blood Cell (RBC) Count at Indicated Time Points (Oral Dose)
Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 1 (post-dose), 14 and 29
Change From Baseline in RBC Count at Indicated Time Points (IM Dose)
Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Weeks 4, 8 and 12
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points (Oral Dose)
SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in SBP and DBP at Indicated Time Points (IM Dose)
SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52
Change From Baseline in Pulse Rate at Indicated Time Points (Oral Dose)
Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in Pulse Rate at Indicated Time Points (IM Dose)
Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52
Change From Baseline in Body Temperature at Indicated Time Points (Oral Dose)
Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 14 and 29
Change From Baseline in Body Temperature at Indicated Time Points (IM Dose)
Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1, Pre-dose), Days 3, 5, 8, Weeks 4, 8, 12, 24, 36, and 52
Number of Participants With Abnormal Urinalysis Parameters Following Oral Administration of Cabotegravir
Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.
Time frame: Up to Day 29
Number of Participants With Abnormal Urinalysis Parameters Following IM Administration of Cabotegravir
Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.
Time frame: Up to Week 52
This was a Phase 1, open label study in healthy participants to assess the pharmacokinetics of cabotegravir (CAB) long-acting (LA) in the blood plasma and anatomical tissues and secretions associated with sexual human immunodeficiency virus (HIV)-1 transmission. The study was conducted across two centers in the United States.
| Milestone | Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg |
|---|---|
| Started | 19 |
| Completed | 18 |
| Not completed | 1 |
| Withdrew: Physician decision | 1 |
| Milestone | Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg |
|---|---|
| Started | 18 |
| Completed | 17 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
| Milestone | Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg |
|---|---|
| Started | 17 |
| Completed | 16 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Blood samples were collected to measure cabotegravir concentration in blood plasma following a single 600 mg IM dose at indicated time-points. Evaluable Pharmacokinetic (PK) Plasma Parameter Summary Population comprised of all participants who underwent plasma PK sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and had evaluable PK parameters estimated and no major protocol deviation.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Day 1: Pre-dose, n=15 | 0.0000 ± NA |
| Day 1: 4 hours, n=15 | 0.2864 ± 0.10463 |
| Day 3, n=15 | 3.2748 ± 1.74419 |
| Day 5, n=15 | 5.1071 ± 3.09180 |
| Day 8, n=15 | 5.0433 ± 2.92704 |
| Week 4, n=15 | 2.5583 ± 1.00963 |
| Week 8, n=15 | 0.9683 ± 0.73601 |
| Week 12, n=15 | 0.3925 ± 0.40471 |
| Week 24, n=15 | 0.0550 ± NA |
| Week 36, n=15 | 0.0213 ± NA |
| Week 52, n=14 | 0.0089 ± NA |
Vaginal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points. Evaluable Tissue-Fluid and PK Parameter Population (Oral plus IM) comprised of all participants who underwent sampling following oral dose in treatment period 1 and IM injection in treatment period 2 and have both evaluable PK and evaluable tissues-fluid parameters estimated in vaginal tissue/cervical tissue/cervicovaginal fluid/rectal tissue/rectal fluid.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.5286 ± 0.48215 |
| Week 8 | 0.1809 ± 0.14606 |
Cervical tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.8016 ± 0.70126 |
| Day 8 | 0.9261 ± 0.85513 |
| Week 4 | 0.4409 ± 0.29216 |
| Week 8 | 0.1570 ± 0.14909 |
| Week 12 | 0.0460 ± NA |
Cervicovaginal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.6604 ± 0.91588 |
| Day 8 | 0.6175 ± 0.59792 |
| Week 4 | 0.3209 ± 0.37093 |
| Week 8 | 0.0905 ± 0.14821 |
| Week 12 | 0.0901 ± 0.18306 |
Rectal tissue samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.2824 ± 0.17814 |
| Day 8 | 0.5146 ± 0.26514 |
| Week 4 | 0.2620 ± 0.10476 |
| Week 8 | 0.1037 ± 0.10050 |
| Week 12 | 0.0348 ± NA |
Rectal fluid samples were collected to measure cabotegravir concentration following a single 600 mg IM dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 1.3868 ± 1.88097 |
| Day 8 | 3.2046 ± 2.68417 |
| Week 4 | 5.2674 ± 7.99949 |
| Week 8 | 0.3233 ± 0.22764 |
| Week 12 | 0.7901 ± 1.75430 |
Vaginal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.128 ± 43.38 |
| Week 8 | 0.199 ± 32.66 |
Cervical tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.203 ± 36.14 |
| Day 8 | 0.174 ± 44.85 |
| Week 4 | 0.139 ± 99.93 |
| Week 8 | 0.139 ± 59.16 |
| Week 12 | 0.101 ± 45.10 |
Cervicovaginal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervicovaginal fluid to cabotegravir concentration in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.116 ± 174.76 |
| Day 8 | 0.124 ± 73.53 |
| Week 4 | 0.073 ± 277.59 |
| Week 8 | 0.057 ± 101.03 |
| Week 12 | 0.082 ± 112.91 |
Cervical tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in cervical tissue to cabotegravir concentration in cervicovaginal fluid is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 1.738 ± 118.75 |
| Day 8 | 1.405 ± 81.10 |
| Week 4 | 1.883 ± 172.44 |
| Week 8 | 2.785 ± 110.92 |
| Week 12 | 1.195 ± 105.01 |
Vaginal tissue and cervicovaginal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in vaginal tissue to cabotegravir concentration in cervicovaginal fluid is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 1.095 ± 233.20 |
| Week 8 | 3.613 ± 115.25 |
Rectal tissue and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.078 ± 43.13 |
| Day 8 | 0.105 ± 22.92 |
| Week 4 | 0.104 ± 18.79 |
| Week 8 | 0.096 ± 27.81 |
| Week 12 | 0.091 ± 38.62 |
Rectal fluid and blood samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal fluid to cabotegravir concentration in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Day 3 | 0.286 ± 157.60 |
| Day 8 | 0.581 ± 140.37 |
| Week 4 | 0.460 ± 923.37 |
| Week 8 | 0.302 ± 140.54 |
| Week 12 | 0.514 ± 185.97 |
Rectal tissue and rectal fluid samples were collected to measure cabotegravir concentration following cabotegravir IM dose at indicated time-points. Data for ratio of cabotegravir concentration in rectal tissue to cabotegravir concentration in rectal fluid is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Day 3, n=11 | 0.271 ± 150.25 |
| Day 8, n=12 | 0.185 ± 140.92 |
| Week 4, n=12 | 0.230 ± 1082.13 |
| Week 8, n=12 | 0.366 ± 133.20 |
| Week 12, n=12 | 0.093 ± 294.16 |
Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Maximum Observed Concentration (Cmax) of Cabotegravir in Blood Plasma Following IM Administration | 5.04 ± 62.0 |
Cervical tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Cmax of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) | 0.81 ± 105.0 |
Cervicovaginal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Cmax of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) | 0.55 ± 118.3 |
Rectal tissue samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Cmax of Cabotegravir in Rectal Tissue Following IM Administration | 0.50 ± 47.0 |
Rectal fluid samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Micrograms per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Cmax of Cabotegravir in Rectal Fluid Following IM Administration | 3.27 ± 171.9 |
Blood samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Time Point (AUC[0-last]) for Cabotegravir in Blood Plasma Following IM Administration | 3992.25 ± 24.5 |
Cervical tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-last) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) | 522.73 ± 77.0 |
Cervicovaginal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-last) of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) | 324.33 ± 121.4 |
Rectal tissue samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-last) for Cabotegravir in Rectal Tissue Following IM Administration | 347.73 ± 35.5 |
Rectal fluid samples were collected to measure AUC(0-last) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-last) for Cabotegravir in Rectal Fluid Following IM Administration | 1841.23 ± 193.8 |
Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Area Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-inf]) for Cabotegravir in Blood Plasma Following IM Administration | 4172.17 ± 23.9 |
Cervical tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-inf) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) | 695.72 ± NA |
Cervicovaginal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-inf) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) | 399.07 ± 99.9 |
Rectal tissue samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-inf) for Cabotegravir in Rectal Tissue Following IM Administration | 291.98 ± 34.6 |
Rectal fluid samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-inf) for Cabotegravir in Rectal Fluid Following IM Administration | 850.05 ± 42.7 |
Blood samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Area Under the Concentration Time Curve From Time Zero to Week (WK) 4 (AUC[0-WK4]) for Cabotegravir in Blood Plasma Following IM Administration | 2141.91 ± 59.2 |
Cervical tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK4) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) | 277.48 ± 103.6 |
Cervicovaginal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK4) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) | 203.32 ± 125.5 |
Rectal tissue samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK4) for Cabotegravir in Rectal Tissue Following IM Administration | 206.28 ± 57.2 |
Rectal fluid samples were collected to measure AUC(0-WK4) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK4) for Cabotegravir in Rectal Fluid Following IM Administration | 1170.49 ± 192.1 |
Blood samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Area Under the Concentration Time Curve From Time Zero to Week 8 (AUC[0-WK8]) for Cabotegravir in Blood Plasma Following IM Administration | 3213.62 ± 40.1 |
Cervical tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK8) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) | 364.74 ± 85.2 |
Cervicovaginal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK8) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) | 281.60 ± 124.8 |
Rectal tissue samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK8) for Cabotegravir in Rectal Tissue Following IM Administration | 287.35 ± 38.7 |
Rectal fluid samples were collected to measure AUC(0-WK8) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK8) for Cabotegravir in Rectal Fluid Following IM Administration | 1575.54 ± 202.9 |
Blood samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| Area Under the Concentration Time Curve From Time Zero to Week 12 (AUC[0-WK12]) for Cabotegravir in Blood Plasma Following IM Administration | 3639.01 ± 35.6 |
Cervical tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK12) for Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) | 349.98 ± 78.9 |
Cervicovaginal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK12) for Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) | 380.92 ± 107.8 |
Rectal tissue samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK12) for Cabotegravir in Rectal Tissue Following IM Administration | 323.91 ± 54.8 |
Rectal fluid samples were collected to measure AUC(0-WK12) at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours*microgram per milliliter | Cabotegravir IM 600 mg |
|---|---|
| AUC(0-WK12) for Cabotegravir in Rectal Fluid Following IM Administration | 1345.13 ± 137.7 |
Blood samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Cabotegravir IM 600 mg |
|---|---|
| Apparent Terminal Phase Half-life (t1/2) of Cabotegravir in Blood Plasma Following IM Administration | 459.53 ± 81.4 |
Cervical tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Cabotegravir IM 600 mg |
|---|---|
| t1/2 of Cabotegravir in Cervical Tissue Following IM Administration (Female Participants) | 363.41 ± NA |
Cervicovaginal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Cabotegravir IM 600 mg |
|---|---|
| t1/2 of Cabotegravir in Cervicovaginal Fluid Following IM Administration (Female Participants) | 355.83 ± 79.4 |
Rectal tissue samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Cabotegravir IM 600 mg |
|---|---|
| t1/2 of Cabotegravir in Rectal Tissue Following IM Administration | 567.48 ± 23.3 |
Rectal fluid samples were collected to measure t1/2 at indicated time-points. Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Cabotegravir IM 600 mg |
|---|---|
| t1/2 of Cabotegravir in Rectal Fluid Following IM Administration | 306.58 ± 3.5 |
Cervical tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervical tissue to AUC(0-last) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-last) in Cervical Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.1215 ± 64.86 |
Rectal tissue and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal tissue to AUC(0-last) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-last) in Rectal Tissue to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration | 0.0849 ± 21.13 |
Cervical tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervical tissue to AUC(0-inf) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-inf) in Cervical Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.1943 ± NA |
Rectal tissue and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal tissue to AUC(0-inf) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-inf) in Rectal Tissue to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration | 0.0766 ± 42.26 |
Cervical tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervical tissue to AUC(0-WK4) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-Wk4) in Cervical Tissue to AUC(0-Wk4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.1553 ± 50.33 |
Rectal tissue and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal tissue to AUC(0-WK4) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-Wk 4) in Rectal Tissue to AUC(0-Wk 4) in Blood Plasma for Cabotegravir Following IM Administration | 0.1000 ± 19.30 |
Cervical tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervical tissue to AUC(0-WK8) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK8) in Cervical Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.1492 ± 52.30 |
Rectal tissue and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal tissue to AUC(0-WK8) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK8) in Rectal Tissue to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration | 0.1062 ± 17.46 |
Cervical tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervical tissue to AUC(0-WK12) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK12) in Cervical Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.1230 ± 48.22 |
Rectal tissue and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal tissue to AUC(0-WK12) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK12) in Rectal Tissue to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration | 0.1089 ± 13.50 |
Cervicovaginal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in cervicovaginal fluid to AUC(0-last) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-last) in Cervicovaginal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration-female Participants | 0.0754 ± 99.37 |
Rectal fluid and blood samples were collected to measure AUC(0-last) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-last) in rectal fluid to AUC(0-last) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-last) in Rectal Fluid to AUC(0-last) in Blood Plasma for Cabotegravir Following IM Administration | 0.4445 ± 204.26 |
Cervicovaginal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in cervicovaginal fluid to AUC(0-inf) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-inf) in Cervicovaginal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.0857 ± 99.10 |
Rectal fluid and blood samples were collected to measure AUC(0-inf) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-inf) in rectal fluid to AUC(0-inf) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-inf) in Rectal Fluid to AUC(0-inf) in Blood Plasma for Cabotegravir Following IM Administration | 0.1949 ± 80.06 |
Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in cervicovaginal fluid to AUC(0-WK4) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK4) in Cervicovaginal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.1032 ± 119.71 |
Rectal fluid and blood samples were collected to measure AUC(0-WK4) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK4) in rectal fluid to AUC(0-WK4) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK4) in Rectal Fluid to AUC(0-WK4) in Blood Plasma for Cabotegravir Following IM Administration | 0.5452 ± 223.58 |
Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in cervicovaginal fluid to AUC(0-WK8) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK8) in Cervicovaginal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.0925 ± 124.99 |
Rectal fluid and blood samples were collected to measure AUC(0-WK8) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK8) in rectal fluid to AUC(0-WK8) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK8) in Rectal Fluid to AUC(0-WK8) in Blood Plasma for Cabotegravir Following IM Administration | 0.4845 ± 212.20 |
Cervicovaginal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in cervicovaginal fluid to AUC(0-WK12) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK12) in Cervicovaginal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration (Female Participants) | 0.0867 ± 99.56 |
Rectal fluid and blood samples were collected to measure AUC(0-WK12) following cabotegravir IM dose at indicated time-points. Data for ratio of AUC(0-WK12) in rectal fluid to AUC(0-WK12) in blood plasma is presented.
| Ratio | Cabotegravir IM 600 mg |
|---|---|
| Ratio of AUC(0-WK12) in Rectal Fluid to AUC(0-WK12) in Blood Plasma for Cabotegravir Following IM Administration | 0.3863 ± 154.56 |
Vaginal tissue samples were collected to measure cabotegravir concentration in vaginal tissue following oral 30 mg dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir Oral 30 mg |
|---|---|
| Cabotegravir Concentration in Vaginal Tissue Following Oral Administration (Female Participants) | 0.7477 ± 0.50171 |
Cervical tissue samples were collected to measure cabotegravir concentration in cervical tissue following oral 30 mg dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir Oral 30 mg |
|---|---|
| Cabotegravir Concentration in Cervical Tissue Following Oral Administration (Female Participants) | 1.1009 ± 0.53987 |
Cervicovaginal fluid samples were collected to measure cabotegravir concentration in cervicovaginal fluid following oral 30 mg dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir Oral 30 mg |
|---|---|
| Cabotegravir Concentration in Cervicovaginal Fluid Following Oral Administration (Female Participants) | 0.8959 ± 0.95662 |
Rectal tissue samples were collected to measure cabotegravir concentration in rectal tissue following oral 30 mg dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir Oral 30 mg |
|---|---|
| Cabotegravir Concentration in Rectal Tissue Following Oral Administration | 0.6104 ± 0.24854 |
Rectal fluid samples were collected to measure cabotegravir concentration in rectal fluid following oral 30 mg dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir Oral 30 mg |
|---|---|
| Cabotegravir Concentration in Rectal Fluid Following Oral Administration | 5.5457 ± 6.41639 |
Blood samples were collected to measure cabotegravir concentration in blood plasma following oral 30 mg dose at indicated time-points.
| Micrograms per milliliter | Cabotegravir Oral 30 mg |
|---|---|
| Cabotegravir Concentration in Blood Plasma Following Oral Administration | 5.7313 ± 2.08899 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.
| Participants | Cabotegravir Oral 30 mg |
|---|---|
| Any Non-SAE | 10 |
| Any SAE | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment, associated with liver injury and impaired liver function was categorized as SAE. Number of participants with any non-SAE and SAE are presented.
| Participants | Cabotegravir IM 600 mg |
|---|---|
| Any Non-SAE | 17 |
| Any SAE | 2 |
Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| International units per Liter | Cabotegravir Oral 30 mg |
|---|---|
| ALT, Day 14 | 1.7 ± 8.98 |
| ALT, Day 29 | 3.5 ± 10.12 |
| ALP, Day 14 | -0.2 ± 6.44 |
| ALP, Day 29 | -0.4 ± 3.24 |
| AST, Day 14 | -0.3 ± 3.60 |
| AST, Day 29 | 1.1 ± 6.14 |
Blood samples were collected for the assessment of clinical chemistry parameters; ALT, ALP and AST following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| International units per Liter | Cabotegravir IM 600 mg |
|---|---|
| ALT, Week 4, n=17 | -0.2 ± 4.05 |
| ALT, Week 8, n=16 | -0.8 ± 5.33 |
| ALT, Week 12, n=16 | -1.4 ± 3.81 |
| ALP, Week 4, n=15 | 2.1 ± 6.39 |
| ALP, Week 8, n=16 | 0.6 ± 8.43 |
| ALP, Week 12, n=16 | 1.3 ± 6.57 |
| AST, Week 4, n=17 | 0.1 ± 2.87 |
| AST, Week 8, n=16 | 0.1 ± 3.76 |
| AST, Week 12, n=16 | -0.1 ± 3.50 |
Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| International units per Liter | Cabotegravir Oral 30 mg |
|---|---|
| Day 14 | -19.9 ± 27.23 |
| Day 29 | -8.9 ± 46.56 |
Blood samples were collected for the assessment of clinical chemistry parameter; creatine kinase following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| International units per Liter | Cabotegravir IM 600 mg |
|---|---|
| Week 8 | 19.6 ± 67.42 |
| Week 12 | 22.2 ± 92.09 |
Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Micromoles per liter | Cabotegravir Oral 30 mg |
|---|---|
| Creatinine, Day 14, n=18 | 0.491 ± 5.6500 |
| Creatinine, Day 29, n=18 | -0.491 ± 7.0929 |
| Direct bilirubin, Day 14, n=11 | -0.311 ± 0.6917 |
| Direct bilirubin, Day 29, n=12 | 0.428 ± 0.7734 |
| Total bilirubin, Day 14, n=16 | -1.282 ± 1.9245 |
| Total bilirubin, Day 29, n=16 | 0.000 ± 2.7217 |
Blood samples were collected for the assessment of clinical chemistry parameters; creatinine, direct bilirubin and total bilirubin following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Micromoles per liter | Cabotegravir IM 600 mg |
|---|---|
| Creatinine, Week 4, n=17 | -3.640 ± 8.3037 |
| Creatinine, Week 8, n=16 | -5.525 ± 5.4732 |
| Creatinine, Week 12, n=16 | -3.315 ± 8.4637 |
| Direct bilirubin, Week 4, n=10 | -0.171 ± 0.5407 |
| Direct bilirubin, Week 8, n=10 | 0.171 ± 1.2617 |
| Direct bilirubin, Week 12, n=9 | 0.190 ± 1.3368 |
| Total bilirubin, Week 4, n=16 | 0.641 ± 3.1142 |
| Total bilirubin, Week 8, n=15 | 0.114 ± 4.2118 |
| Total bilirubin, Week 12, n=14 | 1.099 ± 4.5789 |
Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Grams per liter | Cabotegravir Oral 30 mg |
|---|---|
| Albumin, Day 14 | -0.6 ± 2.85 |
| Albumin, Day 29 | -0.3 ± 1.53 |
| Total protein, Day 14 | -1.7 ± 3.48 |
| Total protein, Day 29 | -1.4 ± 2.23 |
Blood samples were collected for the assessment of clinical chemistry parameters; albumin and total protein following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Grams per liter | Cabotegravir IM 600 mg |
|---|---|
| Albumin, Week 4, n=17 | 0.3 ± 2.66 |
| Albumin, Week 8, n=16 | 0.3 ± 2.41 |
| Albumin, Week 12, n=16 | 0.6 ± 2.42 |
| Total protein, Week 4, n=17 | 0.2 ± 3.23 |
| Total protein, Week 8, n=15 | -0.1 ± 3.53 |
| Total protein, Week 12, n=16 | 0.5 ± 4.31 |
Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and urea enzymatic colorimetry (UEC) following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Millimoles per Liter | Cabotegravir Oral 30 mg |
|---|---|
| Calcium, Day 14 | -0.027722 ± 0.0905221 |
| Calcium, Day 29 | -0.033267 ± 0.0774940 |
| Glucose, Day 14 | 0.391654 ± 0.6929202 |
| Glucose, Day 29 | 0.672288 ± 1.0302415 |
| Potassium, Day 14 | -0.05 ± 0.296 |
| Potassium, Day 29 | -0.04 ± 0.241 |
| Sodium, Day 14 | -0.9 ± 1.53 |
| Sodium, Day 29 | -0.3 ± 2.43 |
| UEC, Day 14 | -0.2975 ± 0.97384 |
| UEC, Day 29 | -0.2578 ± 1.14741 |
Blood samples were collected for the assessment of clinical chemistry parameters; calcium, glucose, potassium, sodium and UEC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Millimoles per Liter | Cabotegravir IM 600 mg |
|---|---|
| Calcium, Week 4, n=17 | -0.002935 ± 0.0763335 |
| Calcium, Week 8, n=15 | -0.003327 ± 0.0610177 |
| Calcium, Week 12, n=16 | -0.001559 ± 0.0666177 |
| Glucose, Week 4, n=17 | -0.111020 ± 0.6467570 |
| Glucose, Week 8, n=16 | -0.003469 ± 0.8073398 |
| Glucose, Week 12, n=16 | -0.149183 ± 0.6402427 |
| Potassium, Week 4, n=17 | -0.08 ± 0.260 |
| Potassium, Week 8, n=16 | -0.07 ± 0.236 |
| Potassium, Week 12, n=16 | 0.01 ± 0.379 |
| Sodium, Week 4, n=17 | -0.4 ± 2.06 |
| Sodium, Week 8, n=16 | 0.1 ± 1.77 |
| Sodium, Week 12, n=16 | -0.6 ± 1.79 |
| UEC, Week 4, n=17 | -0.5250 ± 1.01068 |
| UEC, Week 8, n=16 | -0.6694 ± 1.20801 |
| UEC, Week 12, n=16 | -0.3570 ± 1.18762 |
Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Giga cells per Liter | Cabotegravir Oral 30 mg |
|---|---|
| Basophils, Day 14, n=1 | -0.30 ± NA |
| Basophils, Day 29, n=2 | -0.05 ± 0.212 |
| Eosinophils, Day 14, n=1 | 0.000 ± NA |
| Eosinophils, Day 29, n=2 | 0.100 ± 0.1414 |
| Lymphocytes, Day 14, n=1 | 0.500 ± NA |
| Lymphocytes, Day 29, n=2 | 0.400 ± 0.1414 |
| Monocytes, Day 14, n=1 | 0.000 ± NA |
| Monocytes, Day 29, n=2 | -0.100 ± 0.0000 |
Blood samples were collected for the assessment of hematology parameters; basophil count, eosinophil count, lymphocyte count and monocyte count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Giga cells per Liter | Cabotegravir IM 600 mg |
|---|---|
| Basophils, Week 4, n=3 | 0.03 ± 0.058 |
| Basophils, Week 8, n=1 | 0.00 ± NA |
| Eosinophils, Week 4, n=3 | 0.000 ± 0.0000 |
| Eosinophils, Week 8, n=1 | 0.000 ± NA |
| Lymphocytes, Week 4, n=3 | 0.073 ± 0.3607 |
| Lymphocytes, Week 8, n=1 | -0.300 ± NA |
| Monocytes, Week 4, n=3 | -0.040 ± 0.2425 |
| Monocytes, Week 8, n=1 | 0.000 ± NA |
Blood samples were collected for the assessment of hematology parameter; total neutrophils count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Giga cells per Liter | Cabotegravir Oral 30 mg |
|---|---|
| Day 14, n=9 | -0.353 ± 0.6194 |
| Day 29, n=11 | -0.565 ± 1.1071 |
Blood samples were collected for the assessment of hematology parameters; total neutrophil count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Giga cells per Liter | Cabotegravir IM 600 mg |
|---|---|
| Week 4, n=11 | 0.539 ± 0.9379 |
| Week 8, n=8 | 0.010 ± 0.8206 |
| Week 12, n=7 | -0.076 ± 0.7115 |
Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Giga cells per Liter | Cabotegravir Oral 30 mg |
|---|---|
| Platelets, Day 1 (post-dose), n=1 | 39.0 ± NA |
| Platelets, Day 14, n=17 | -6.6 ± 30.83 |
| Platelets, Day 29, n=18 | 8.7 ± 29.14 |
| WBCs, Day 1, n=1 | 2.100 ± NA |
| WBCs, Day 14, n=17 | -0.056 ± 0.8815 |
| WBCs, Day 29, n=18 | -0.263 ± 1.1894 |
Blood samples were collected for the assessment of hematology parameters; platelet count and WBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Giga cells per Liter | Cabotegravir IM 600 mg |
|---|---|
| Platelets, Week 4, n=17 | 11.7 ± 21.00 |
| Platelets, Week 8, n=16 | 12.0 ± 25.72 |
| Platelets, Week 12, n=16 | 7.3 ± 18.34 |
| WBCs, Week 4, n=17 | -0.053 ± 1.1486 |
| WBCs, Week 8, n=16 | -0.085 ± 0.7777 |
| WBCs, Week 12, n=16 | -0.159 ± 0.9395 |
Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Grams per Liter | Cabotegravir Oral 30 mg |
|---|---|
| Hemoglobin, Day 1 (post-dose), n=1 | -6.0 ± NA |
| Hemoglobin, Day 14, n=17 | -5.1 ± 7.60 |
| Hemoglobin, Day 29, n=18 | -3.6 ± 6.93 |
| MCHC, Day 1 (post-dose), n=1 | -8.0 ± NA |
| MCHC, Day 14, n=17 | -1.2 ± 6.93 |
| MCHC, Day 29, n=18 | 1.3 ± 7.81 |
Blood samples were collected for the assessment of hematology parameters; hemoglobin and MCHC following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Grams per Liter | Cabotegravir IM 600 mg |
|---|---|
| Hemoglobin, Week 4, n=17 | -0.8 ± 5.25 |
| Hemoglobin, Week 8, n=16 | 0.8 ± 6.56 |
| Hemoglobin, Week 12, n=16 | 1.4 ± 7.31 |
| MCHC, Week 4, n=17 | 0.9 ± 7.39 |
| MCHC, Week 8, n=16 | -0.8 ± 6.33 |
| MCHC, Week 12, n=16 | 1.8 ± 6.84 |
Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Picograms | Cabotegravir Oral 30 mg |
|---|---|
| Day 1 (post-dose), n=1 | -0.90 ± NA |
| Day 14, n=17 | -0.22 ± 0.629 |
| Day 29, n=18 | -0.01 ± 0.567 |
Blood samples were collected for the assessment of hematology parameter; MCH following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Picograms | Cabotegravir IM 600 mg |
|---|---|
| Week 4, n=17 | -0.15 ± 0.292 |
| Week 8, n=16 | -0.39 ± 0.584 |
| Week 12, n=16 | -0.36 ± 0.778 |
Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Femtoliters | Cabotegravir Oral 30 mg |
|---|---|
| Day 1 (post-dose), n=1 | -0.20 ± NA |
| Day 14, n=17 | -0.40 ± 1.052 |
| Day 29, n=18 | -0.34 ± 1.303 |
Blood samples were collected for the assessment of hematology parameter; MCV following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Femtoliters | Cabotegravir IM 600 mg |
|---|---|
| Week 4, n=17 | -0.67 ± 1.771 |
| Week 8, n=16 | -1.03 ± 1.799 |
| Week 12, n=16 | -1.63 ± 1.861 |
Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Proportion of red blood cells in blood | Cabotegravir Oral 30 mg |
|---|---|
| Day 1 (post-dose), n=1 | -0.0060 ± NA |
| Day 14, n=17 | -0.0135 ± 0.02456 |
| Day 29, n=18 | -0.0122 ± 0.02084 |
Blood samples were collected for the assessment of hematology parameter; hematocrit following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Proportion of red blood cells in blood | Cabotegravir IM 600 mg |
|---|---|
| Week 4, n=17 | -0.0034 ± 0.01703 |
| Week 8, n=16 | 0.0030 ± 0.02145 |
| Week 12, n=16 | 0.0025 ± 0.02196 |
Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir oral dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Trillion cells per liter | Cabotegravir Oral 30 mg |
|---|---|
| Day 1 (post-dose), n=1 | -0.050 ± NA |
| Day 14, n=17 | -0.126 ± 0.2813 |
| Day 29, n=18 | -0.114 ± 0.2360 |
Blood samples were collected for the assessment of hematology parameter; RBC count following cabotegravir IM dose at indicated time-points. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Trillion cells per liter | Cabotegravir IM 600 mg |
|---|---|
| Week 4, n=17 | -0.004 ± 0.1718 |
| Week 8, n=16 | 0.087 ± 0.2129 |
| Week 12, n=16 | 0.117 ± 0.2266 |
SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Millimeters of mercury | Cabotegravir Oral 30 mg |
|---|---|
| SBP, Day 14 | -1.3 ± 8.55 |
| SBP, Day 29 | -1.0 ± 8.64 |
| DBP, Day 14 | -0.9 ± 7.57 |
| DBP, Day 29 | 0.5 ± 5.96 |
SBP and DBP were measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Millimeters of mercury | Cabotegravir IM 600 mg |
|---|---|
| SBP, Day 3, n=17 | 0.1 ± 10.15 |
| SBP, Day 5, n=17 | -1.5 ± 10.44 |
| SBP, Day 8, n=17 | 3.2 ± 13.18 |
| SBP, Week 4, n=17 | 1.8 ± 12.11 |
| SBP, Week 8, n=16 | 0.9 ± 9.23 |
| SBP, Week 12, n=16 | -1.1 ± 11.69 |
| SBP, Week 24, n=16 | 2.0 ± 12.88 |
| SBP, Week 36, n=16 | 1.7 ± 11.44 |
| SBP, Week 52, n=15 | 0.7 ± 13.08 |
| DBP, Day 3, n=17 | 0.5 ± 4.11 |
| DBP, Day 5, n=17 | -0.7 ± 4.69 |
| DBP, Day 8, n=17 | 0.6 ± 5.36 |
| DBP, Week 4, n=17 | -0.4 ± 5.20 |
| DBP, Week 8, n=16 | 3.3 ± 5.65 |
| DBP, Week 12, n=16 | 0.2 ± 4.46 |
| DBP, Week 24, n=16 | 1.0 ± 4.98 |
| DBP, Week 36, n=16 | 2.3 ± 5.47 |
| DBP, Week 52, n=15 | 0.1 ± 9.23 |
Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Beats per minute | Cabotegravir Oral 30 mg |
|---|---|
| Day 14 | -1.0 ± 5.72 |
| Day 29 | 2.4 ± 8.23 |
Pulse rate was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Beats per minute | Cabotegravir IM 600 mg |
|---|---|
| Day 3, n=17 | -0.9 ± 10.51 |
| Day 5, n=17 | 6.2 ± 7.66 |
| Day 8, n=17 | 1.6 ± 9.06 |
| Week 4, n=17 | -0.6 ± 7.40 |
| Week 8, n=16 | -0.9 ± 7.85 |
| Week 12, n=16 | 1.3 ± 11.80 |
| Week 24, n=16 | 1.1 ± 6.87 |
| Week 36, n=16 | 2.6 ± 11.07 |
| Week 52, n=15 | 1.9 ± 10.59 |
Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Degrees Celsius | Cabotegravir Oral 30 mg |
|---|---|
| Day 14 | -0.2 ± 0.54 |
| Day 29 | -0.1 ± 0.46 |
Body temperature was measured in a semi-supine position after approximately 10 minutes rest. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose (Day 1) assessment with a non-missing value, including those from unscheduled visits.
| Degrees Celsius | Cabotegravir IM 600 mg |
|---|---|
| Day 3, n=17 | -0.0 ± 0.36 |
| Day 5, n=17 | 0.2 ± 0.52 |
| Day 8, n=17 | 0.0 ± 0.37 |
| Week 4, n=17 | -0.1 ± 0.31 |
| Week 8, n=16 | -0.0 ± 0.47 |
| Week 12, n=16 | 0.2 ± 0.37 |
| Week 24, n=16 | -0.0 ± 0.39 |
| Week 36, n=16 | -0.1 ± 0.58 |
| Week 52, n=15 | 0.1 ± 0.61 |
Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.
No measurements were reported for this outcome.
Urinalysis included assessment of pH, glucose, protein, blood and ketones by dipstick method. This analysis was not planned and data was not collected and not captured in the database.
No measurements were reported for this outcome.
Collected over Non-SAEs and SAEs were collected from the start of study treatment up to Day 29 for Period 1 (Oral dose) and up to Week 52 for Period 2 (IM dose). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabotegravir Oral 30 mg | 0/19 (0%) | 0/19 (0%) | 10/19 (52.6%) |
| Cabotegravir IM 600 mg | 0/17 (0%) | 2/17 (11.8%) | 17/17 (100%) |
| Event | Cabotegravir Oral 30 mg | Cabotegravir IM 600 mg |
|---|---|---|
| Pupils unequalEye disorders | 0/19 | 1/17 |
| DysphagiaGastrointestinal disorders | 0/19 | 1/17 |
| Urinary tract infectionInfections and infestations | 0/19 | 1/17 |
| AphasiaNervous system disorders | 0/19 | 1/17 |
| Cerebral haemorrhageNervous system disorders | 0/19 | 1/17 |
| Migraine with auraNervous system disorders | 0/19 | 1/17 |
| Serotonin syndromeNervous system disorders | 0/19 | 1/17 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/19 | 1/17 |
| Post-traumatic stress disorderPsychiatric disorders | 0/19 | 1/17 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/19 | 1/17 |
| Event | Cabotegravir Oral 30 mg | Cabotegravir IM 600 mg |
|---|---|---|
| Injection site painGeneral disorders | 0/19 | 15/17 |
| Gastroenteritis viralInfections and infestations | 3/19 | 0/17 |
| Injection site erythemaGeneral disorders | 0/19 | 2/17 |
| PyrexiaGeneral disorders | 0/19 | 2/17 |
| DepressionPsychiatric disorders | 0/19 | 2/17 |
| InsomniaPsychiatric disorders | 0/19 | 2/17 |
| PalpitationsCardiac disorders | 0/19 | 2/17 |
| HeadacheNervous system disorders | 0/19 | 2/17 |
| Blood glucose increasedInvestigations | 2/19 | 0/17 |
| FatigueGeneral disorders | 1/19 | 1/17 |
| Age, Continuous(Years) | Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg |
|---|---|
| Mean | 33.3 ± 9.12 |
| Sex: Female, Male(Participants) | Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg |
|---|---|
| Female | 10 |
| Male | 9 |
| Race/Ethnicity, Customized(Participants) | Cabotegravir Oral 30 mg Followed by Cabotegravir IM 600 mg |
|---|---|
| Asian - South East Asian Heritage | 1 |
| Black or African American | 6 |
| White - White/Caucasian/European Heritage | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Jul 2019, 28 months.
Results were first posted in Jun 2020, 10 months after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 28 months is above that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir